Table 1.
Demographics and clinicopathologic characteristics of patients with ICC
| Primary Cohort (n=370) | Validation cohort (n=115) | P value | |
|---|---|---|---|
|
|
|||
| No. of patients (%) | No. of patients (%) | ||
| Gender | 0.780 | ||
| male | 236 (63.8) | 75 (65.2) | |
| female | 134 (36.2) | 40 (34.8) | |
| Age (≥ 65 years) | 81 (21.9) | 19 (16.5) | 0.214 |
| HBV infection | 187 (50.5) | 51 (44.3) | 0.246 |
| Seropositive anti-HCV | 10 (2.7) | 2 (1.7) | 0.740 |
| Hepatolithiasis | 36 (9.7) | 11 (9.6) | 0.958 |
| Liver schistosomiasis | 22 (5.9) | 7 (6.1) | 0.956 |
| ALT (> 41 U/L) | 103 (27.8) | 29 (25.2) | 0.581 |
| AST (> 37 U/L) | 110 (29.7) | 30 (26.1) | 0.451 |
| PA (< 170 mg/L) | 71 (19.2) | 29 (25.2) | 0.163 |
| TBIL (> 20 µmol/L) | 59 (15.9) | 15 (13.0) | 0.450 |
| r-GT (> 61 U/L) | 214 (57.8) | 60 (52.2) | 0.285 |
| ALP (> 129 U/L) | 129 (34.9) | 34 (29.6) | 0.293 |
| AFP (> 20 µg/L) | 74 (20.0) | 16 (13.9) | 0.142 |
| CA19-9 (> 39 U/mL) | 200 (54.1) | 58 (50.4) | 0.497 |
| CEA (> 10 µg/L) | 55 (14.9) | 19 (16.5) | 0.666 |
| Tumor size (cm) | 0.353 | ||
| < 5 | 130 (35.1) | 35 (30.4) | |
| ≥ 5 | 240 (64.9) | 80 (69.6) | |
| Tumor number | 0.944 | ||
| single | 233 (63.0) | 72 (62.6) | |
| multiple | 137 (37.0) | 43 (37.4) | |
| Cirrhosis | 115 (31.1) | 29 (25.2) | 0.229 |
| Capsule formation | 32 (8.6) | 6 (5.2) | 0.232 |
| Tumor differentiation | 0.825 | ||
| well to moderately | 334 (90.3) | 103 (89.6) | |
| poorly | 36 (9.7) | 12 (10.4) | |
| Vascular invasion | 112 (30.3) | 29 (25.2) | 0.297 |
| Regional lymphatic metastasis | 70 (18.9) | 27 (23.5) | 0.286 |
| Local extrahepatic metastasis | 67 (18.1) | 16 (13.9) | 0.297 |
| 6th TNM | 0.327 | ||
| Stage I | 148 (40.0) | 40 (34.8) | |
| Stage II | 31 (8.4) | 16 (13.9) | |
| Stage III | 158 (42.7) | 48 (41.7) | |
| Stage IV | 33 (8.9) | 11 (9.6) | |
| 7th TNM | 0.232 | ||
| Stage I | 146 (39.5) | 39 (33.9) | |
| Stage II | 105 (28.4) | 40 (34.8) | |
| Stage III | 23 (6.2) | 3 (2.6) | |
| Stage IV | 96 (25.9) | 33 (28.7) | |
ICC: intrahepatic cholangiocarcinoma; HBV: hepatitis B virus; HCV: hepatitis C virus; M: male; F: female; Prealbumin: PA; TBIL: total bilirubin; alanine transaminase (ALT); aspartate transaminase (AST); ALP: alkaline phosphatase; r-GT: r-glutamyltransferase; AFP: Alpha-fetoprotein; CA19-9: carbohydrate antigen 19-9, CEA: carcinoembryonic antigen.